Product
DAN-222
1 clinical trial
1 indication
Indication
HER2-negative Metastatic Breast CancerClinical trial
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast CancerStatus: Completed, Estimated PCD: 2023-09-13